Xspray Pharma
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development, the first XS004 dasatinib recently filed with the FDA. Xspray’s strategy is to improve the quality of life for cancer patients by launching improved PKI products with relevant medical benefits and cost effectiveness. Xspray Pharma uses its innovative, patented RightSize™ technology to develop 505(b)(2) improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs), for the treatment of cancer. The segment is the second largest in oncology and where drug prices are very high. Xspray Pharma applies a unique platform technology: - Improves the solubility of the active ingredient - Best-in-class for high dose strength for poorly soluble drugs - Fully amorphous (non-infringing to many crystalline products patents)
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-15 08:00 |
Interim Report
|
Swedish | 1018.3 KB | |
| 2025-08-15 08:00 |
Interim Report
|
English | 1020.5 KB | |
| 2025-08-15 07:50 |
Share Issue/Capital Change
Xspray beslutar om en företrädesemission om cirka 130 MSEK med en övertilldelni…
|
Swedish | 77.5 KB | |
| 2025-08-15 07:50 |
Share Issue/Capital Change
Xspray resolves on a rights issue of approximately SEK 130 million with an over…
|
English | 77.5 KB | |
| 2025-08-12 08:18 |
Regulatory News Service
Xspray Pharma tecknar licensavtal med Handa Therapeutics – erhåller upp till tv…
|
Swedish | 44.4 KB | |
| 2025-08-12 08:18 |
M&A Activity
Xspray Pharma signs license agreement with Handa Therapeutics – to receive up t…
|
English | 44.2 KB | |
| 2025-07-11 14:10 |
Regulatory News Service
XSpray Pharma achieves significant milestone – demonstrating bioequivalence wit…
|
English | 45.6 KB | |
| 2025-07-11 14:10 |
Regulatory News Service
XSpray Pharma uppnår betydande milstolpe – visar bioekvivalens med absorptionsf…
|
Swedish | 45.8 KB | |
| 2025-06-27 15:55 |
Regulatory News Service
Xspray Pharma Passes FDA Pre-Approval Inspection – Key Regulatory Milestone Ach…
|
English | 44.2 KB | |
| 2025-06-27 15:55 |
Regulatory News Service
Xspray Pharma Klarar FDA:s Pre-Approval Inspection – Viktig Regulatorisk Milsto…
|
Swedish | 43.9 KB | |
| 2025-05-14 21:10 |
Regulatory News Service
FDA meddelar PDUFA-datum för Xspray Pharmas kompletterade ansökan för Dasynoc®
|
Swedish | 44.6 KB | |
| 2025-05-14 21:10 |
Regulatory News Service
FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc®
|
English | 44.1 KB | |
| 2025-05-13 11:03 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Xspray Pharma AB (publ)
|
Swedish | 45.5 KB | |
| 2025-05-13 11:03 |
Post-Annual General Meeting Information
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
|
English | 44.2 KB | |
| 2025-05-07 08:00 |
Quarterly Report
|
Swedish | 901.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-13 | Anders Bladh | Other | Buy | 7,141 | 281,855.27 SEK |
| 2023-11-10 | Anders Bladh | Other | Buy | 42,859 | 1,578,925.56 SEK |
| 2023-11-09 | Anders Bladh | Other | Buy | 18,129 | 670,410.42 EUR |
| 2023-11-08 | Anders Bladh | Other | Buy | 81,871 | 2,751,684.31 SEK |
| 2023-05-29 | Kerstin Hasselgren | Other | Buy | 10,000 | 55,200.00 SEK |
| 2023-05-25 | Per Andersson | Other | Buy | 37,830 | 208,821.60 SEK |
| 2023-05-02 | Anders Ekblom | Other | Buy | 25,000 | 1,247,205.00 SEK |
| 2023-03-17 | Anders Bladh | Other | Buy | 20,000 | 1,400,000.00 SEK |
| 2023-03-13 | Anders Bladh | Other | Buy | 30,000 | 2,160,000.00 SEK |
| 2023-03-13 | Per Andersson | Other | Sell | 30,000 | 2,160,000.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |